{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T06:52:04Z","timestamp":1776408724711,"version":"3.51.2"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-06954-w","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T07:45:34Z","timestamp":1774683934000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Integrated transcriptome-proteome analysis in patients with myelofibrosis-related anemia"],"prefix":"10.1007","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2646-4359","authenticated-orcid":false,"given":"Liqing","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9411-1427","authenticated-orcid":false,"given":"Yuanzhong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2873-0334","authenticated-orcid":false,"given":"Yong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,28]]},"reference":[{"key":"6954_CR1","doi-asserted-by":"publisher","first-page":"5901","DOI":"10.1158\/1078-0432.CCR-18-4089","volume":"25","author":"B Woods","year":"2019","unstructured":"Woods B et al (2019) Activation of JAK\/STAT signaling in megakaryocytes sustains myeloproliferation in vivo. Clin Cancer Res 25:5901\u20135912. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-4089","journal-title":"Clin Cancer Res"},{"key":"6954_CR2","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.6004\/jnccn.2022.0046","volume":"20","author":"AT Gerds","year":"2022","unstructured":"Gerds AT et al (2022) Myeloproliferative neoplasms, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 20:1033\u20131062. https:\/\/doi.org\/10.6004\/jnccn.2022.0046","journal-title":"J Natl Compr Canc Netw"},{"key":"6954_CR3","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13045-021-01116-z","volume":"14","author":"G Greenfield","year":"2021","unstructured":"Greenfield G, McMullin MF, Mills K (2021) Molecular pathogenesis of the myeloproliferative neoplasms. J Hematol Oncol 14:103. https:\/\/doi.org\/10.1186\/s13045-021-01116-z","journal-title":"J Hematol Oncol"},{"key":"6954_CR4","doi-asserted-by":"publisher","first-page":"103862","DOI":"10.1016\/j.critrevonc.2022.103862","volume":"180","author":"F Passamonti","year":"2022","unstructured":"Passamonti F et al (2022) Anemia in myelofibrosis: current and emerging treatment options. Crit Rev Oncol Hematol 180:103862. https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103862","journal-title":"Crit Rev Oncol Hematol"},{"key":"6954_CR5","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","volume":"363","author":"S Verstovsek","year":"2010","unstructured":"Verstovsek S et al (2010) Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 363:1117\u20131127. https:\/\/doi.org\/10.1056\/NEJMoa1002028","journal-title":"N Engl J Med"},{"key":"6954_CR6","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1038\/s41375-018-0028-x","volume":"32","author":"M Nicolosi","year":"2018","unstructured":"Nicolosi M et al (2018) Sex and degree of severity influence the prognostic impact of anemia in primary myelofibrosis: analysis based on 1109 consecutive patients. Leukemia 32:1254\u20131258. https:\/\/doi.org\/10.1038\/s41375-018-0028-x","journal-title":"Leukemia"},{"key":"6954_CR7","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1002\/cncr.35156","volume":"130","author":"F Palandri","year":"2024","unstructured":"Palandri F et al (2024) Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy. Cancer 130:1270\u20131280. https:\/\/doi.org\/10.1002\/cncr.35156","journal-title":"Cancer"},{"issue":"4","key":"6954_CR8","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/ajh.27659","volume":"100","author":"N Gangat","year":"2025","unstructured":"Gangat N, Tefferi A (2025) Emerging pathogenetic mechanisms and new drugs for anemia in myelofibrosis and myelodysplastic syndromes. Am J Hematol 100(4):51\u201365. https:\/\/doi.org\/10.1002\/ajh.27659","journal-title":"Am J Hematol"},{"key":"6954_CR9","doi-asserted-by":"publisher","first-page":"683401","DOI":"10.3389\/fimmu.2021.683401","volume":"12","author":"DAC Fisher","year":"2021","unstructured":"Fisher DAC, Fowles JS, Zhou A, Oh ST (2021) Inflammatory pathophysiology as a contributor to myeloproliferative neoplasms. Front Immunol 12:683401. https:\/\/doi.org\/10.3389\/fimmu.2021.683401","journal-title":"Front Immunol"},{"key":"6954_CR10","doi-asserted-by":"publisher","first-page":"6392","DOI":"10.1182\/blood-2011-04-348144","volume":"118","author":"AG Fleischman","year":"2011","unstructured":"Fleischman AG et al (2011) TNFalpha facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms. Blood 118:6392\u20136398. https:\/\/doi.org\/10.1182\/blood-2011-04-348144","journal-title":"Blood"},{"key":"6954_CR11","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1186\/s12964-024-01877-3","volume":"22","author":"E Peroni","year":"2024","unstructured":"Peroni E, Calistri E, Amato R, Gottardi M, Rosato A (2024) Spatial-transcriptomic profiling: a new lens for understanding myelofibrosis pathophysiology. Cell Commun Signal 22:510. https:\/\/doi.org\/10.1186\/s12964-024-01877-3","journal-title":"Cell Commun Signal"},{"key":"6954_CR12","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD et al (2022) The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia 36:1703\u20131719. https:\/\/doi.org\/10.1038\/s41375-022-01613-1","journal-title":"Leukemia"},{"key":"6954_CR13","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","volume":"115","author":"F Passamonti","year":"2010","unstructured":"Passamonti F et al (2010) A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 115:1703\u20131708. https:\/\/doi.org\/10.1182\/blood-2009-09-245837","journal-title":"Blood"},{"key":"6954_CR14","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1515\/CCLM.2000.026","volume":"38","author":"C Mannhalter","year":"2000","unstructured":"Mannhalter C, Koizar D, Mitterbauer G (2000) Evaluation of RNA isolation methods and reference genes for RT-PCR analyses of rare target RNA. Clin Chem Lab Med 38:171\u2013177. https:\/\/doi.org\/10.1515\/CCLM.2000.026","journal-title":"Clin Chem Lab Med"},{"key":"6954_CR15","doi-asserted-by":"publisher","first-page":"e95192","DOI":"10.1371\/journal.pone.0095192","volume":"9","author":"E Assarsson","year":"2014","unstructured":"Assarsson E et al (2014) Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS ONE 9:e95192. https:\/\/doi.org\/10.1371\/journal.pone.0095192","journal-title":"PLoS ONE"},{"key":"6954_CR16","doi-asserted-by":"publisher","first-page":"3605","DOI":"10.1007\/s00277-024-05847-0","volume":"103","author":"L Wang","year":"2024","unstructured":"Wang L et al (2024) Treatment of myelofibrosis with refractory anemia with luspatercept: a multicenter Chinese study. Ann Hematol 103:3605\u20133613. https:\/\/doi.org\/10.1007\/s00277-024-05847-0","journal-title":"Ann Hematol"},{"key":"6954_CR17","doi-asserted-by":"publisher","first-page":"D672","DOI":"10.1093\/nar\/gkae909","volume":"53","author":"M Kanehisa","year":"2025","unstructured":"Kanehisa M, Furumichi M, Sato Y, Matsuura Y, Ishiguro-Watanabe M (2025) KEGG: biological systems database as a model of the real world. Nucleic Acids Res 53:D672\u2013D677. https:\/\/doi.org\/10.1093\/nar\/gkae909","journal-title":"Nucleic Acids Res"},{"key":"6954_CR18","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1038\/s41467-019-09234-6","volume":"10","author":"Y Zhou","year":"2019","unstructured":"Zhou Y et al (2019) Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun 10:1523. https:\/\/doi.org\/10.1038\/s41467-019-09234-6","journal-title":"Nat Commun"},{"key":"6954_CR19","doi-asserted-by":"publisher","first-page":"13476","DOI":"10.1038\/ncomms13476","volume":"7","author":"D Chmiest","year":"2016","unstructured":"Chmiest D et al (2016) Spatiotemporal control of interferon-induced JAK\/STAT signalling and gene transcription by the retromer complex. Nat Commun 7:13476. https:\/\/doi.org\/10.1038\/ncomms13476","journal-title":"Nat Commun"},{"key":"6954_CR20","doi-asserted-by":"publisher","first-page":"eabe4627","DOI":"10.1126\/scisignal.abe4627","volume":"14","author":"M Shemesh","year":"2021","unstructured":"Shemesh M, Lochte S, Piehler J, Schreiber G (2021) IFNAR1 and IFNAR2 play distinct roles in initiating type I interferon-induced JAK-STAT signaling and activating STATs. Sci Signal 14:eabe4627. https:\/\/doi.org\/10.1126\/scisignal.abe4627","journal-title":"Sci Signal"},{"key":"6954_CR21","doi-asserted-by":"publisher","first-page":"3536","DOI":"10.1182\/blood-2014-11-575357","volume":"125","author":"D Kuhrt","year":"2015","unstructured":"Kuhrt D, Wojchowski DM, Emerging (2015) EPO and EPO receptor regulators and signal transducers. Blood 125:3536\u20133541. https:\/\/doi.org\/10.1182\/blood-2014-11-575357","journal-title":"Blood"},{"key":"6954_CR22","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1007\/s00277-021-04615-8","volume":"100","author":"J Baumeister","year":"2021","unstructured":"Baumeister J et al (2021) Early and late stage MPN patients show distinct gene expression profiles in CD34(+) cells. Ann Hematol 100:2943\u20132956. https:\/\/doi.org\/10.1007\/s00277-021-04615-8","journal-title":"Ann Hematol"},{"key":"6954_CR23","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1158\/1078-0432.CCR-23-0372","volume":"30","author":"M Kandarpa","year":"2024","unstructured":"Kandarpa M et al (2024) Broad next-generation integrated sequencing of myelofibrosis identifies disease-specific and age-related genomic alterations. Clin Cancer Res 30:1972\u20131983. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-0372","journal-title":"Clin Cancer Res"},{"key":"6954_CR24","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s12967-015-0474-4","volume":"CXCL13","author":"B Wu","year":"2015","unstructured":"Wu B et al (2015) CCL4, and sTNFR as circulating inflammatory cytokine markers in primary and SLE-related autoimmune hemolytic anemia. J Transl Med 13 CXCL13:112. https:\/\/doi.org\/10.1186\/s12967-015-0474-4","journal-title":"J Transl Med 13"},{"key":"6954_CR25","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1097\/MOH.0b013e3282f15fa6","volume":"15","author":"P Secchiero","year":"2008","unstructured":"Secchiero P, Zauli G (2008) Tumor-necrosis-factor-related apoptosis-inducing ligand and the regulation of hematopoiesis. Curr Opin Hematol 15:42\u201348. https:\/\/doi.org\/10.1097\/MOH.0b013e3282f15fa6","journal-title":"Curr Opin Hematol"},{"key":"6954_CR26","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.3324\/haematol.2011.056705","volume":"97","author":"U Fischer","year":"2012","unstructured":"Fischer U et al (2012) CD34\u2009+\u2009gene expression profiling of individual children with very severe aplastic anemia indicates a pathogenic role of integrin receptors and the proapoptotic death ligand TRAIL. Haematologica 97:1304\u20131311. https:\/\/doi.org\/10.3324\/haematol.2011.056705","journal-title":"Haematologica"},{"key":"6954_CR27","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/S0002-9440(10)62277-8","volume":"166","author":"D Campioni","year":"2005","unstructured":"Campioni D et al (2005) Evidence for a role of TNF-related apoptosis-inducing ligand (TRAIL) in the anemia of myelodysplastic syndromes. Am J Pathol 166:557\u2013563. https:\/\/doi.org\/10.1016\/S0002-9440(10)62277-8","journal-title":"Am J Pathol"},{"key":"6954_CR28","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1182\/blood-2003-06-2137","volume":"103","author":"P Secchiero","year":"2004","unstructured":"Secchiero P et al (2004) TRAIL regulates normal erythroid maturation through an ERK-dependent pathway. Blood 103:517\u2013522. https:\/\/doi.org\/10.1182\/blood-2003-06-2137","journal-title":"Blood"},{"key":"6954_CR29","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1182\/blood.v99.4.1305","volume":"99","author":"F Silvestris","year":"2002","unstructured":"Silvestris F, Cafforio P, Tucci M, Dammacco F (2002) Negative regulation of erythroblast maturation by Fas-L(+)\/TRAIL(+) highly malignant plasma cells: a major pathogenetic mechanism of anemia in multiple myeloma. Blood 99:1305\u20131313. https:\/\/doi.org\/10.1182\/blood.v99.4.1305","journal-title":"Blood"},{"key":"6954_CR30","first-page":"375","volume":"25","author":"S Sancilio","year":"2011","unstructured":"Sancilio S et al (2011) TRAIL promotes a pro-survival signal in erythropoietin-deprived human erythroblasts through the activation of an NF-kB\/IkBalpha pathway. J Biol Regul Homeost Agents 25:375\u2013386","journal-title":"J Biol Regul Homeost Agents"},{"key":"6954_CR31","doi-asserted-by":"publisher","first-page":"1209249","DOI":"10.3389\/fimmu.2023.1209249","volume":"14","author":"S Gunalp","year":"2023","unstructured":"Gunalp S et al (2023) TRAIL promotes the polarization of human macrophages toward a proinflammatory M1 phenotype and is associated with increased survival in cancer patients with high tumor macrophage content. Front Immunol 14:1209249. https:\/\/doi.org\/10.3389\/fimmu.2023.1209249","journal-title":"Front Immunol"},{"key":"6954_CR32","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1038\/s41375-019-0379-y","volume":"33","author":"DAC Fisher","year":"2019","unstructured":"Fisher DAC et al (2019) Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NFkappaB signaling. Leukemia 33:1978\u20131995. https:\/\/doi.org\/10.1038\/s41375-019-0379-y","journal-title":"Leukemia"},{"key":"6954_CR33","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","volume":"29","author":"A Tefferi","year":"2011","unstructured":"Tefferi A et al (2011) Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol 29:1356\u20131363. https:\/\/doi.org\/10.1200\/JCO.2010.32.9490","journal-title":"J Clin Oncol"},{"key":"6954_CR34","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1186\/s12885-024-12301-x","volume":"24","author":"H Xiong","year":"2024","unstructured":"Xiong H et al (2024) Associations of the circulating levels of cytokines with the risk of myeloproliferative neoplasms: a bidirectional mendelian-randomization study. BMC Cancer 24:531. https:\/\/doi.org\/10.1186\/s12885-024-12301-x","journal-title":"BMC Cancer"},{"key":"6954_CR35","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1182\/blood.V89.4.1147","volume":"89","author":"L Oehler","year":"1997","unstructured":"Oehler L et al (1997) Interleukin-10 inhibits spontaneous colony-forming unit-granulocyte-macrophage growth from human peripheral blood mononuclear cells by suppression of endogenous granulocyte-macrophage colony-stimulating factor release. Blood 89:1147\u20131153","journal-title":"Blood"},{"key":"6954_CR36","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/ejh.12486","volume":"95","author":"K Geissler","year":"2015","unstructured":"Geissler K et al (2015) Interleukin-10 inhibits autonomous myelopoiesis in patients with myelofibrosis. Eur J Haematol 95:239\u2013243. https:\/\/doi.org\/10.1111\/ejh.12486","journal-title":"Eur J Haematol"},{"key":"6954_CR37","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1182\/bloodadvances.2018026450","volume":"3","author":"HY Lai","year":"2019","unstructured":"Lai HY et al (2019) Defective negative regulation of Toll-like receptor signaling leads to excessive TNF-alpha in myeloproliferative neoplasm. Blood Adv 3:122\u2013131. https:\/\/doi.org\/10.1182\/bloodadvances.2018026450","journal-title":"Blood Adv"},{"key":"6954_CR38","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1186\/s12890-024-03260-x","volume":"24","author":"Y Li","year":"2024","unstructured":"Li Y et al (2024) IL-10 deficiency aggravates cell senescence and accelerates BLM-induced pulmonary fibrosis in aged mice via PTEN\/AKT\/ERK pathway. BMC Pulm Med 24:443. https:\/\/doi.org\/10.1186\/s12890-024-03260-x","journal-title":"BMC Pulm Med"},{"key":"6954_CR39","doi-asserted-by":"publisher","unstructured":"Khan MA et al (2021) IL-10 mediated immunomodulation limits subepithelial fibrosis and repairs airway epithelium in rejecting airway allografts. Cells 10:1248. https:\/\/doi.org\/10.3390\/cells10051248","DOI":"10.3390\/cells10051248"},{"key":"6954_CR40","doi-asserted-by":"publisher","first-page":"2003533","DOI":"10.1080\/2162402X.2021.2003533","volume":"10","author":"K Stirm","year":"2021","unstructured":"Stirm K et al (2021) Tumor cell-derived IL-10 promotes cell-autonomous growth and immune escape in diffuse large B-cell lymphoma. Oncoimmunology 10:2003533. https:\/\/doi.org\/10.1080\/2162402X.2021.2003533","journal-title":"Oncoimmunology"},{"key":"6954_CR41","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/s12967-015-0590-1","volume":"13","author":"G Musuraca","year":"2015","unstructured":"Musuraca G et al (2015) IL-17\/IL-10 double-producing T cells: new link between infections, immunosuppression and acute myeloid leukemia. J Transl Med 13:229. https:\/\/doi.org\/10.1186\/s12967-015-0590-1","journal-title":"J Transl Med"},{"key":"6954_CR42","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/S0140-6736(22)02036-0","volume":"401","author":"S Verstovsek","year":"2023","unstructured":"Verstovsek S et al (2023) Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study. Lancet 401:269\u2013280. https:\/\/doi.org\/10.1016\/S0140-6736(22)02036-0","journal-title":"Lancet"},{"key":"6954_CR43","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/s41408-024-01202-8","volume":"14","author":"Y Zhang","year":"2024","unstructured":"Zhang Y et al (2024) Evaluation of gecacitinib vs hydroxyurea in patients with intermediate-2 or high-risk myelofibrosis: final analysis results from a randomized phase 3 study. Blood Cancer J 14:216. https:\/\/doi.org\/10.1038\/s41408-024-01202-8","journal-title":"Blood Cancer J"},{"key":"6954_CR44","doi-asserted-by":"publisher","first-page":"4511","DOI":"10.1182\/bloodadvances.2024012939","volume":"8","author":"AT Gerds","year":"2024","unstructured":"Gerds AT et al (2024) Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis. Blood Adv 8:4511\u20134522. https:\/\/doi.org\/10.1182\/bloodadvances.2024012939","journal-title":"Blood Adv"},{"key":"6954_CR45","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/ejh.13198","volume":"102","author":"G Birgegard","year":"2019","unstructured":"Birgegard G et al (2019) Inflammatory functional iron deficiency common in myelofibrosis, contributes to anaemia and impairs quality of life. From the Nordic MPN study Group. Eur J Haematol 102:235\u2013240. https:\/\/doi.org\/10.1111\/ejh.13198","journal-title":"Eur J Haematol"},{"key":"6954_CR46","doi-asserted-by":"publisher","first-page":"e49","DOI":"10.1111\/bjh.18044","volume":"197","author":"A Zhou","year":"2022","unstructured":"Zhou A et al (2022) Hepcidin is elevated in primary and secondary myelofibrosis and remains elevated in patients treated with ruxolitinib. Br J Haematol 197:e49\u2013e52. https:\/\/doi.org\/10.1111\/bjh.18044","journal-title":"Br J Haematol"},{"key":"6954_CR47","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1002\/ajh.23406","volume":"88","author":"A Pardanani","year":"2013","unstructured":"Pardanani A, Finke C, Abdelrahman RA, Lasho TL, Tefferi A (2013) Associations and prognostic interactions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosis. Am J Hematol 88:312\u2013316. https:\/\/doi.org\/10.1002\/ajh.23406","journal-title":"Am J Hematol"},{"key":"6954_CR48","doi-asserted-by":"publisher","first-page":"5710","DOI":"10.1182\/blood-2010-07-293761","volume":"117","author":"J Thiele","year":"2011","unstructured":"Thiele J et al (2011) Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification. Blood 117:5710\u20135718. https:\/\/doi.org\/10.1182\/blood-2010-07-293761","journal-title":"Blood"},{"key":"6954_CR49","doi-asserted-by":"publisher","first-page":"e0161570","DOI":"10.1371\/journal.pone.0161570","volume":"11","author":"V Skov","year":"2016","unstructured":"Skov V et al (2016) A 7-gene signature depicts the biochemical profile of early prefibrotic myelofibrosis. PLoS ONE 11:e0161570. https:\/\/doi.org\/10.1371\/journal.pone.0161570","journal-title":"PLoS ONE"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06954-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06954-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06954-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T06:00:01Z","timestamp":1776405601000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06954-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,28]]},"references-count":49,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["6954"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06954-w","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,28]]},"assertion":[{"value":"6 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the ethics committee of Fujian Medical University Union Hospital (Approval no. 2025YF022-01) and was performed in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval statement"}},{"value":"Written informed consent for data collection and publication was obtained from each participant prior to the enrollment of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent statement"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"211"}}